Want to see NGEN full AI Analyst Report?

NervGen Pharma (NGEN) Price & Analysis

123 Followers

NGEN Stock Chart & Stats

$4.07

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$4.07

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$1.58 - $6.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)818.53K

Market Cap

$144.66M

Enterprise Value$289.36

Total Cash (Recent Filing)$16.55M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.52

Next Earnings

Nov 12, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding82,193,140

10 Day Avg. Volume880,572

30 Day Avg. Volume818,526

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)159.85

Price to Sales (P/S)0.00

P/FCF Ratio-28.50

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-0.02

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$10.33

Price Target Upside153.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.24

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Progress / Phase 3 AlignmentIndependent, blinded biomechanical gait analyses showed statistically significant, multi-domain neural recovery signals and aligned with prior electrophysiology and function gains. This durable clinical signal and FDA End-of-Phase 2 alignment materially de-risks the program and supports a registrational Phase 3 pathway that could establish first-mover positioning in chronic spinal cord injury if replicated.

Recent Institutional FinancingA successful underwritten offering with institutional bookrunners provides validated access to capital, materially extending the development runway for NVG-291 and enabling Phase 3 initiation and site activation. Durable impact: institutional backing reduces near-term financing execution risk and supports continuity of late-stage development activities.

Low Leverage / Minimal DebtA very low-debt profile lowers fixed financial obligations and bankruptcy risk, giving management flexibility to fund R&D through equity or non-debt mechanisms. For a clinical-stage biotech, low leverage is a persistent risk mitigant that preserves optionality for multi-year registrational programs and strategic partnerships.

Bears Say

Pre-revenue With Widening LossesBeing pre-revenue means long-term value hinges entirely on successful clinical outcomes and regulatory approval. Widening multi-year losses increase cumulative funding needs and heighten the consequences of trial delays or negative readouts, making the business structurally dependent on future financing or partnerships to reach commercialization.

High And Increasing Cash BurnRising operating cash outflows materially shorten runway and force frequent capital raises or resource reallocation. Persistent negative free cash flow constrains strategic optionality, raises execution risk for lengthy registrational programs, and increases sensitivity to market conditions when seeking financing over the next several quarters.

Dependence On Equity Markets / Dilution RiskFrequent reliance on equity—illustrated by the ATM and recent underwritten offering—means ongoing dilution for shareholders and exposure to market windows. Structurally, this dependence can pressure ownership, require management to balance financing timing with trial pacing, and leave program funding contingent on investor appetite rather than internal cash generation.

NervGen Pharma News

NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position

NervGen Pharma ( ($NGEN) ) has issued an update. NervGen Pharma Corp., a Vancouver-based biotechnology company specializing in...

1d ago

NGEN

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18...

1M ago

NGEN

NervGen Pharma initiated with an Outperform at Leerink

Leerink analyst Marc Goodman initiated coverage of NervGen Pharma (NGEN) with an Outperform rating and $10 price target...

1M ago

NGEN

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

NervGen Pharma ( ($NGEN) ) has issued an update. On July 2, 2026, NervGen Pharma filed a Form...

1M ago

NGEN

NervGen Pharma initiated with a Buy at TD Cowen

TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company...

2M ago

NGEN

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma priced an underwritten...

2M ago

NGEN

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A...

3M ago

NGEN

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

NervGen Pharma ( ($NGEN) ) has provided an update. On May 26, 2026, NervGen Pharma reported independently conducted,...

3M ago

NGEN

NervGen Pharma files $250M mixed securities shelf

09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

NGEN

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...

3M ago

NGEN

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma announced it had...

3M ago

NGEN

NervGen Pharma 24M share Spot Secondary priced at $2.50

Leerink and TD Cowen acted as joint book running managers for the offering. Published first on TheFly –...

3M ago

NGEN

NervGen Pharma secondary being re-offered at $2.50 per share

Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering. Published first on TheFly...

3M ago

NGEN

NervGen Pharma announces common share offering, no amount given

NervGen Pharma (NGEN) Corp. announced that it has commenced an underwritten public offering of common shares and accompanying...

3M ago

NGEN

NGEN FAQ

What was Nervgen Pharma Corp’s price range in the past 12 months?

Nervgen Pharma Corp lowest stock price was $1.58 and its highest was $6.30 in the past 12 months.

What is Nervgen Pharma Corp’s market cap?

Nervgen Pharma Corp’s market cap is $144.66M.

When is Nervgen Pharma Corp’s upcoming earnings report date?

Nervgen Pharma Corp’s upcoming earnings report date is Nov 12, 2026 which is in 90 days.

How were Nervgen Pharma Corp’s earnings last quarter?

Nervgen Pharma Corp released its earnings results on Aug 13, 2026. The company reported -$0.265 earnings per share for the quarter, missing the consensus estimate of -$0.061 by -$0.204.

Is Nervgen Pharma Corp overvalued?

According to Wall Street analysts Nervgen Pharma Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nervgen Pharma Corp pay dividends?

Nervgen Pharma Corp does not currently pay dividends.

What is Nervgen Pharma Corp’s EPS estimate?

Nervgen Pharma Corp’s EPS estimate is -0.08.

How many shares outstanding does Nervgen Pharma Corp have?

Nervgen Pharma Corp has 82,193,140 shares outstanding.

What happened to Nervgen Pharma Corp’s price movement after its last earnings report?

Nervgen Pharma Corp reported an EPS of -$0.265 in its last earnings report, missing expectations of -$0.061. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nervgen Pharma Corp?

Currently, no hedge funds are holding shares in NGEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

NervGen Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

35.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nervgen Pharma Corp

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

NervGen Pharma (NGEN) Earnings & Revenues

Historic Earnings Reports

NGEN Stock 12 Month Forecast

Average Price Target

$10.33

▲(153.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.333333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.649230769230769,3.6784615384615384,4.707692307692308,5.736923076923077,6.766153846153846,7.795384615384616,8.824615384615385,9.853846153846153,10.883076923076924,11.912307692307692,12.94153846153846,13.970769230769232,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.2902564102564105,2.960512820512821,3.630769230769231,4.3010256410256416,4.971282051282052,5.641538461538462,6.311794871794873,6.982051282051283,7.652307692307693,8.322564102564105,8.992820512820515,9.663076923076925,{"y":10.333333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.956923076923077,2.293846153846154,2.630769230769231,2.9676923076923076,3.304615384615385,3.641538461538462,3.9784615384615387,4.315384615384616,4.6523076923076925,4.989230769230769,5.326153846153846,5.663076923076924,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.597,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.524,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >